Highlights from the 15th Annual Congress of EAHAD

Highlights from the 15th Annual Congress of EAHAD

EXPLORE™ Module

EXPLORE™ Module

A self-paced, interactive
learning experience

Click to Begin!

Train-the-Trainer Toolkit

Train-the-Trainer Toolkit

Prepare for the future approval of a gene therapy in hemophilia

Interactive Webinar

Interactive Webinar

Obstacles and Opportunities
Presented by: Frank W.G. Leebeek, MD, PhD

Click to Begin!

Interactive Webinar

Conference Coverage

Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Conference Coverage

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Conference Coverage

Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B

Conference Coverage

Improvements in Health-Related Quality of Life in Adults With Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

MOST POPULAR

Hemophilia Gene Therapy — Readying for Clinical Care: Webinar Series

Hemophilia Gene Therapy — Readying for Clinical Care: Webinar Series

Interactive WebinarsBy Super User19 October 2022

ISTH Gene Therapy in Hemophilia Train-the-Trainer

ToolkitBy Super User29 September 2021

Long-term Outcomes: Durability and Safety

Long-term Outcomes: Durability and Safety

Interactive WebinarsBy Super User28 January 2021

Patient Support, Patient Counseling, and Monitoring

Patient Support, Patient Counseling, and Monitoring

Interactive WebinarsBy Super User23 September 2020

HTC Readiness: A Global Perspective

HTC Readiness: A Global Perspective

PodcastsBy Super User22 September 2020

Latest News

BioMarin Says FDA No Longer Plans Advisory Meeting for Roctavian

24 November 2022

FDA Approves First Gene Therapy to Treat Adults with Hemophilia B

23 November 2022

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ Approved by European Commission (EC)

24 August 2022

Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

10 July 2022

BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

24 June 2022

Conference Coverage

Highlights From the 30th Congress of ISTH

CME INFORMATION

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Anna Sternberg, PhD

Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B

Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B

Guy Young, MD

Improvements in Health-Related Quality of Life in Adults With Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

Improvements in Health-Related Quality of Life in Adults With Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

Steven W. Pipe, M

I agree with the Terms and conditions and the Privacy policy

About

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL